The most recent study identified CISD2 as a new biomarker for the first time for the detection of ferroptosis-associated drug resistance generated in HCC cells induced by sorafenib and regulated by CISD2 via autophagy (Li et al., 2021). This evidence concerns the gene CISD2 and hepatocellular carcinoma.